Followers | 29 |
Posts | 6477 |
Boards Moderated | 0 |
Alias Born | 05/17/2011 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, June 03, 2019 9:00:24 AM
Recent RGNX News
- REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients • PR Newswire (US) • 06/24/2024 11:05:00 AM
- REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II • PR Newswire (US) • 06/18/2024 11:05:00 AM
- REGENXBIO Announces Leadership Transition • PR Newswire (US) • 06/12/2024 11:05:00 AM
- REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:43:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:42:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:41:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:41:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:35:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:06:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 08:22:51 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/10/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:16:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:26 PM
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/08/2024 08:05:00 PM
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/01/2024 11:05:00 AM
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit • PR Newswire (US) • 04/24/2024 11:05:00 AM
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD • PR Newswire (US) • 03/28/2024 11:05:00 AM
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days • PR Newswire (US) • 03/27/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:00:31 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/11/2024 11:05:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 11:09:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:05:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/07/2024 11:03:26 AM
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants • PR Newswire (US) • 03/07/2024 04:20:00 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM